公开(公告)号：US20170037138A1

公开(公告)日：2017-02-09

申请号：US15072983

申请日：2016-03-17

Applicant: GENMAB A/S

Inventor： Janine SCHUURMAN ,  Tom VINK ,  Jan VAN DE WINKEL ,  Aran Frank LABRIJN ,  Paul PARREN ,  Willem Karel BLEEKER ,  Frank BEURSKENS ,  Patrick VAN BERKEL

IPC: C07K16/28

CPC classification number: C07K16/2887 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/283 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/90 ,  C12N15/8509 ,  C12N2740/16011

Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

Abstract translation: 本发明涉及新型非人转基因动物，其在抗原刺激时能够产生结合选定抗原的单价抗体，修饰的重链转基因，用于产生非人转基因动物的方法，用于免疫非人转基因动物的方法 动物以及通过这种免疫方法可获得的单价抗体。

公开(公告)号：US20160130362A1

公开(公告)日：2016-05-12

申请号：US14878797

申请日：2015-10-08

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Yvo GRAUS ,  Judith OPRINS ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Martine VAN VUGT

IPC: C07K16/40 ,  G01N33/566 ,  A61K49/00 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人CD38结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 还公开了包含人抗体的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20160053020A1

公开(公告)日：2016-02-25

申请号：US14839514

申请日：2015-08-28

Applicant: GENMAB A/S

Inventor： Sandra VERPLOEGEN ,  David P.E. SATIJN ,  Rene M.A. HOET ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Vibeke Miller BREINHOLT ,  Eva EHRNROOTH ,  Ole BAADSGAARD ,  Tom VINK ,  Willem Karel BLEEKER ,  Mischa HOUTKAMP ,  Maroeska OUDSHOORN ,  Rob N. DE JONG

IPC: C07K16/36

CPC classification number: C07K16/36 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了结合人TF和相关的基于抗体的组合物和分子的分离的人单克隆抗体。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。

公开(公告)号：US20150368345A1

公开(公告)日：2015-12-24

申请号：US14739771

申请日：2015-06-15

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Laster

IPC: C07K16/28

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of lgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Abstract translation: 本发明涉及抗体的恒定区，特别是1gG4的CH3区，其影响CH3-CH3相互作用强度的位置。 公开了稳定或不稳定这种相互作用的突变。

公开(公告)号：US20140170156A1

公开(公告)日：2014-06-19

申请号：US14074226

申请日：2013-11-07

Applicant: GENMAB A/S

Inventor： Jessica TEELING ,  Paul PARREN ,  Ole BAADSGAARD ,  Debra HUDSON ,  Jørgen PETERSEN

IPC: C07K16/24 ,  G01N33/68 ,  C07K16/42 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/6869

Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与IL-8结合的分离的人单克隆抗体（例如人IL-8）。 人抗体可以通过进行V-D-J重组和同种型转换，在能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人转基因动物例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物，杂交瘤和产生人抗体的转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20130345406A1

公开(公告)日：2013-12-26

申请号：US13912581

申请日：2013-06-07

Applicant: Genmab A/S

Inventor： Jan Van De Winkel ,  Tom Vink ,  Janine Schuurman ,  Paul Parren ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschoten

IPC: C07K16/18 ,  C07K16/16

CPC classification number: C07K16/2887 ,  A61K47/6803 ,  A61K47/6813 ,  A61K47/6835 ,  A61K47/6839 ,  A61K47/6845 ,  A61K47/6849 ,  A61K51/10 ,  A61K51/1006 ,  A61K51/1021 ,  A61K51/1027 ,  A61K51/103 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/16 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/94

Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Abstract translation: 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。

公开(公告)号：US20030091561A1

公开(公告)日：2003-05-15

申请号：US10172317

申请日：2002-06-13

Applicant: GENMAB A/S

Inventor： Jan G.J. van de Winkel ,  Marcus A. van Dijk ,  Arnout F. Gerritsen ,  Edward Halk

IPC: A61K039/395 ,  C12N005/06 ,  C07K016/28

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/732

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US12246025B2

公开(公告)日：2025-03-11

申请号：US16982008

申请日：2019-03-20

Applicant: Genmab A/S

Inventor： Reshma Abdulla Rangwala ,  Esther C. W. Breij ,  Sandra Verploegen ,  Oyewale O. Abidoye ,  Leonardo Viana Nicacio

IPC: C07K16/36 ,  A61K9/00 ,  A61K31/555 ,  A61K33/243 ,  A61K47/68 ,  A61P35/00

Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.

公开(公告)号：US20250066506A1

公开(公告)日：2025-02-27

申请号：US18596319

申请日：2024-03-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Patrick VAN BERKEL ,  Kristin STRUMANE ,  Aran Frank LABRIJN ,  Joost J. NEIJSSEN ,  Joyce I. MEESTERS ,  Paul PARREN ,  Janine SCHUURMAN

IPC: C07K16/32 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  C07K16/10 ,  C07K16/28 ,  C07K16/46

Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.

公开(公告)号：US20250002600A1

公开(公告)日：2025-01-02

申请号：US18696689

申请日：2022-10-05

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Alexander MUIK ,  Kristina SCHÖDEL ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN ,  Sina FELLERMEIER-KOPF ,  Patricia GARRIDO CASTRO ,  Jordan BLUM ,  Friederike GIESEKE ,  Esther C. W. BREIJ ,  Lars GUELEN ,  Joost NEIJSSEN ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Bart-Jan DE KREUK ,  Richard G. HIBBERT ,  Janine SCHUURMAN ,  Aran LABRIJN ,  Ivan KUZMANOV

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.